Mephedrone (4-MMC) - Knowledge Compendium. History, Pharmacology, Research

Mephedrone is a synthetic cathinone that in barely two decades has gone from a forgotten laboratory curiosity to one of the most frequently used psychoactive substances in Europe. According to the PolDrugs 2025 study, 58.7% of Polish users of new psychoactive substances (NPS) report contact with mephedrone or related synthetic cathinones. Despite the growing scale of the phenomenon, knowledge about the pharmacology, metabolism, and actual toxicity profile of 4-MMC remains fragmentary even among professionals. This compendium gathers the most important scientific data in one place.

In brief

• Mephedrone (4-MMC) is a synthetic cathinone with the formula C₁₁H₁₅NO, first synthesised in 1929 and rediscovered in 2003

• It acts as a substrate for monoamine transporters (SERT, DAT, NET), causing full serotonin release and partial dopamine release

• Its elimination half-life is only 2.15 hours - far shorter than MDMA (7.89 h), which promotes compulsive redosing

• In 2023, 53 synthetic cathinone laboratories were dismantled across Europe, 40 of them in Poland

What is mephedrone - chemical classification

Mephedrone, also known as 4-methylmethcathinone (4-MMC), belongs to the synthetic cathinone family - derivatives of cathinone, an alkaloid naturally found in the leaves of the Catha edulis shrub (khat). Structurally, it is a beta-keto analogue of 4-methylmethamphetamine.

Physicochemical data of mephedrone (4-MMC)

IUPAC name	2-(methylamino)-1-(4-methylphenyl)propan-1-one
Molecular formula	C₁₁H₁₅NO
Molar mass	177.24 g/mol (base); 213.70 g/mol (hydrochloride)
CAS number	1189805-46-6
Melting point	145–150 °C (hydrochloride)
Appearance	White or off-white crystalline powder

In hydrochloride form, mephedrone is readily soluble in water, enabling oral, intranasal, and intravenous administration. On the drug market, the substance goes by numerous slang names - meow meow, drone, M-CAT, bubbles, or white magic in English-speaking countries; in Poland, the most common term is simply "mef."

History of discovery and path to market

The synthesis of mephedrone was first described in 1929 by Saem de Burnaga Sanchez in the Bulletin de la Société Chimique de France under the technical name "toluyl-alpha-monomethylaminoethylcetone." For the next seven decades, the compound remained purely a laboratory curiosity - no one investigated its psychoactive properties. The "rediscovery" was made in 2003 by an anonymous chemist using the pseudonym Kinetic, who published the synthesis on The Hive forum - one of the first online repositories of recreational chemistry. This marked a turning point. Just a year later, a legal substance called hagigat, containing a cathinone similar to mephedrone, appeared on the Israeli market. When the Israeli government banned it, the company Neorganics introduced a modified version under the brand Neodoves. Ultimately, in 2008, Israel banned mephedrone - becoming the first country in the world to do so. In Europe, mephedrone spread rapidly between 2008 and 2010, sold legally as "plant food" or "bath salts" labelled not for human consumption. This strategy allowed sellers to circumvent regulations on psychoactive substance trade. Peak popularity came in the United Kingdom, where a 2009 Mixmag readers survey ranked mephedrone as the fourth most commonly used substance - behind cannabis, cocaine, and ecstasy.

Pharmacology - mechanism of action

Mephedrone acts on three major monoamine transporters in the central nervous system: the serotonin transporter (SERT), the dopamine transporter (DAT), and the norepinephrine transporter (NET). Research by Simmler et al. (2013) showed that 4-MMC acts as a full SERT substrate, triggering massive serotonin release, while at the DAT it behaves as a partial substrate - dopamine release is significant but lower than with amphetamine or methamphetamine. It is precisely this ratio of serotonergic to dopaminergic activity that gives mephedrone its characteristic profile - combining psychomotor stimulation (dopaminergic component) with an entactogenic effect, meaning enhanced empathy and feelings of closeness (serotonergic component). In this regard, mephedrone's pharmacology is closer to MDMA than to classical psychostimulants. A controlled clinical study by Dolder et al. (2016), conducted with 12 healthy volunteers, provided the first data from controlled human administration of mephedrone. A 200 mg dose produced subjective effects similar to 100 mg of MDMA, but with an earlier peak (0.75 h vs 1–1.5 h) and shorter duration (2–3 h vs 4 h).

Cardiovascular effects - Dolder et al. study (2016)

Parameter	Mephedrone 200 mg	MDMA 100 mg
Heart rate increase	+28 bpm	+19 bpm
Systolic BP increase	+33.5 mmHg	+33.7 mmHg
Diastolic BP increase	+12.3 mmHg	+15.3 mmHg
Pupil dilation (max.)	+0.87 mm	+1.76 mm

The short duration of mephedrone's effects has significant clinical implications. Effects wear off quickly, leading to compulsive redosing - a phenomenon less commonly seen with MDMA. This compulsive pattern increases both the risk of overdose and the pace of developing drug addiction.

Pharmacokinetics and metabolism

Mephedrone is rapidly absorbed after oral administration. Mean peak plasma concentration (C_max) is 134.6 ng/ml, reached at approximately 1.25 hours (T_max). After 12 hours, levels drop to 6.1 ng/ml, and after 24 hours the substance is undetectable in blood. The elimination half-life is 2.15 hours - one of the shortest among popular psychoactive substances:

Comparison of psychoactive substance half-lives

Substance	Half-life
Mephedrone	2.15 h
Cathinone	~4 h
MDMA	7.89 h
Amphetamine / methamphetamine	~12 h

Mephedrone is metabolised primarily by the CYP2D6 enzyme (cytochrome P450 2D6). Main metabolic pathways include N-demethylation, ketone group reduction, and tolyl group oxidation. Several metabolites have been identified in plasma and urine - nor-mephedrone, dihydro-mephedrone, hydroxytolyl-mephedrone, and 4-carboxy-mephedrone, with the latter being most abundantly excreted. The metabolite N-succinyl-nor-mephedrone has the longest half-life of all metabolites - 8.2 hours - making it a useful marker in toxicological diagnostics. CYP2D6 genetic polymorphism has clinical significance: poor metabolisers may experience stronger and more prolonged effects at the same dose, increasing the risk of toxicity.

Neurotoxicity - what the research says

The question of mephedrone neurotoxicity remains one of the most complex issues in the toxicology of this substance. A systematic review by López-Arnau et al. (2015) revealed a significant dependence of toxic effects on dose, dosing schedule, and - particularly interestingly - ambient temperature.

Serotonin

Under elevated temperature conditions (≥27 °C), mephedrone causes persistent serotonergic deficits - a 40–48% decrease in SERT activity in the frontal cortex and hippocampus, persisting for at least 7 days. At room temperature (20–23 °C), similar changes were not observed. This dependence resembles the toxicity profile of MDMA and suggests that conditions typical of clubs or festivals may significantly amplify neuronal damage.

Dopamine

Research by Angoa-Pérez et al. (2013) demonstrated that mephedrone administered alone does not damage dopaminergic nerve endings in the striatum. However, the surprising discovery was that 4-MMC significantly enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA when combined with them. This toxicity enhancement was independent of hyperthermia - it operated through an independent mechanism, likely by modifying the metabolism of co-administered substances. This finding has serious clinical implications, as combining substances is a common practice.

Oxidative stress and memory

Animal studies have noted increased lipid peroxidation in the frontal cortex, DNA damage, and working memory deficits persisting for over a week after exposure. In vitro cytotoxicity of mephedrone exceeded that observed for MDMA at concentrations above 500 μM. It should be emphasised that most data comes from animal studies, and extrapolation to humans requires caution. Controlled human neurotoxicity studies of mephedrone have not yet been conducted.

Mephedrone in numbers - epidemiology

The scale of mephedrone and synthetic cathinone use has been rising continuously for over a decade, both in Poland and across Europe. Poland - PolDrugs 2025 data:

• 58.7% of NPS users report contact with synthetic cathinones (up from 44% in 2021)

• 32.6% of those seeking medical help after drug use point to mephedrone or related cathinones - up from 19.4% in 2023

• 51.4% of respondents measure doses "by eye," and 83.6% never test substances with colorimetric reagents

School-age youth - ESPAD 2024:

• Poland recorded the highest NPS use rate among students in Europe - 6.4% (lifetime prevalence)

Europe - European Drug Report 2025 (EUDA):

• In 2023, 37 tonnes of synthetic cathinones were seized (up from 27 tonnes in 2022)

• 53 production laboratories were dismantled - 40 of them were in Poland

• 2.1 tonnes of chemical precursors were seized, including 735 kg in Poland

• Treatment entries for cathinone-related issues rose from 425 in 2018 to 1,930 in 2023 (a 356% increase)

• In 2023, 39 deaths involving synthetic cathinones were recorded across 7 European countries

These data indicate that Poland plays a dual role in the European synthetic cathinone ecosystem - as both the primary producer and one of the countries with the highest usage rates.

Legal status in Poland and worldwide

Mephedrone is illegal in the vast majority of countries. Ban timeline:

• 2008 - Israel (first country) and Sweden

• 2010 - United Kingdom, Germany, France, Poland (2010), 15 EU countries in total

• 2010 (December) - EU-wide ban (Council of the EU decision)

• 2012 - USA (Schedule I, Controlled Substances Act)

• 2015 - Global ban (UN Commission on Narcotic Drugs)

In Poland, mephedrone is listed among psychotropic substances in the annex to the Act of 29 July 2005 on Counteracting Drug Addiction. A July 2018 amendment incorporated new psychoactive substances (NPS) into the legal definition of controlled drugs, which also covered cathinone derivatives. This means that introducing successive analogues with minimal chemical modifications is now prosecutable without the need to list each one individually. Possession of mephedrone in Poland is subject to criminal liability under the provisions of the Act on Counteracting Drug Addiction - analogously to other psychotropic substances from group I-P.

Frequently asked questions

How does mephedrone differ from MDMA?

Both compounds act on monoamine transporters, but mephedrone has a significantly shorter half-life (2.15 h vs 7.89 h), weaker pupil dilation effects, and causes a stronger heart rate increase. The short duration of mephedrone promotes compulsive redosing, which is less commonly observed with MDMA. In terms of subjective effects, 200 mg of mephedrone produces effects similar to 100 mg of MDMA.

Does mephedrone cause permanent brain damage?

Animal studies indicate the possibility of persistent serotonergic deficits, particularly with repeated administration at elevated ambient temperatures. Mephedrone alone does not damage dopaminergic nerve endings, but it enhances the neurotoxicity of other substances (methamphetamine, amphetamine, MDMA) when used simultaneously. Controlled neurotoxicity studies in humans have not been conducted.

How long is mephedrone detectable in the body?

Mephedrone is undetectable in blood 24 hours after administration. Its metabolite N-succinyl-nor-mephedrone persists longer (half-life of 8.2 h) and serves as the primary marker in toxicological diagnostics. Detection time in urine depends on dose and frequency of use.

Why is mephedrone so popular in Poland?

Poland is simultaneously Europe's main producer of synthetic cathinones (40 of 53 dismantled laboratories in 2023) and the country with the highest rate of NPS use among school-age youth in Europe (6.4%). Availability, low cost, and the short duration of effects (which forces redosing) are the factors driving the substance's popularity.

Where to seek help for mephedrone addiction?

People addicted to mephedrone should seek professional help. Treatment includes drug detox under medical supervision and addiction therapy, which addresses the psychological mechanisms of addiction. It is important to remember that the recovery process is multi-stage and requires specialist support.

---